
Fatty Acids and Lypidic Derivatives
Found 32454 products of "Fatty Acids and Lypidic Derivatives"
3-(4,6-Dichloro-2-(ethoxycarbonyl)-1H-indol-3-yl)acrylic acid
CAS:Purity:95.0%Molecular weight:328.14999389648441-[3-(Difluoromethoxy)phenyl]-5-oxopyrrolidine-3-carboxylic acid
CAS:Purity:97.0%Molecular weight:271.2200012207031(S)-2-(4-(2-(2-Amino-4-oxo-4,7-dihydro-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl)benzamido)pentanedioic acid
CAS:Purity:95.0%Color and Shape:Solid, Blue powderMolecular weight:427.41699218752-Hydroxy-2-(3-hydroxy-4-methoxyphenyl)acetic acid
CAS:Purity:95.0%Color and Shape:Solid, White crystalline powder, can change colour duringMolecular weight:198.1739959716797Ref: 10-F328950
Discontinued product4-{[2-methyl-6-(trifluoromethyl)pyridin-3-yl]amino}-4-oxobut-2-enoic acid
CAS:Molecular weight:274.1990051269531Atorvastatin epoxydione impurity
CAS:Atorvastatin epoxydione impurity (EPI) is a heptanoic, hydrate, diastereoisomer, racemic mixture, enantiomer and impurity of Atorvastatin. The EPI has been minimized in the formulation process by using a novel synthesis route that employs a chiral pyrrole derivative as an intermediate. This minimization has allowed for the elimination of the tautomer and other impurities present in the original compound.
Formula:C26H22FNO4Purity:Min. 95 Area-%Color and Shape:White PowderMolecular weight:431.46 g/molRef: 3D-IA18016
Discontinued product6-Epi pravastatin sodium
CAS:6-Epi pravastatin sodium salt is a synthetic compound with the same molecular formula and chemical structure as the natural product. It has been used in pharmacological studies, drug development, and research. 6-Epi pravastatin sodium salt is a metabolite of pravastatin.
Formula:C23H36O7•NaPurity:Min. 92.0 Area-%Molecular weight:447.51 g/molRef: 3D-IE34975
Discontinued productPitavastatin 3S,5R isomer calcium
CAS:Pitavastatin 3S,5R isomer Calcium Salt is a potent inhibitor of cholesterol biosynthesis. It is marketed as the hemihydrate form under the trade name Pravacol and is used in the treatment of type 2 diabetes. Pitavastatin 3S,5R isomer Calcium Salt inhibits cholesterol biosynthesis by blocking HMG-CoA reductase, which converts 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) to mevalonate (MVA). The active metabolite, pitavastatin, binds to the regulatory region of HMG-CoA reductase and prevents it from converting MVA to HMG-CoA. This reduces the pool of HMG-CoA available for conversion to cholesterol. The inhibition of this enzyme slows down the production of cholesterol and decreases blood levels. It has been approved for use in adults with type 2 diabetes and for lowering highFormula:(C25H24FNO4)2•CaPurity:Min. 95%Color and Shape:White/Off-White SolidMolecular weight:880.98 g/molRef: 3D-IP145451
Discontinued productAtorvastatin impurity F
CAS:Atorvastatin impurity F is an impurity that can be found in atorvastatin. It is a white to off-white crystalline solid with a melting point of 142°C. It has a molecular weight of 273.5 and chemical formula of C14H13N3O2. This impurity can be found in atorvastatin as an API impurity, which may have an effect on the efficacy or toxicity of the drug product. Impurities are present in all pharmaceutical products and should be identified, characterized, and quantified for quality control purposes. Impurities are often unavoidable byproducts of the manufacturing process and can lead to potential safety concerns if they are not detected early on during drug development. The presence of impurities may also affect the pharmacological effects or therapeutic efficacy of the drug product.
Formula:C40H47FN3O8NaPurity:Min. 95%Color and Shape:PowderMolecular weight:739.8 g/molRef: 3D-FA165540
Discontinued productAtorvastatin methyl ester
CAS:Atorvastatin methyl ester is a statin drug that inhibits the synthesis of cholesterol and other lipids in the body. It is used to reduce high levels of low-density lipoprotein (LDL) cholesterol, which may lead to heart disease or stroke. Atorvastatin methyl ester has been shown to be effective in reducing the uptake of LDL cholesterol into cells by preventing the formation of LDL particles. This drug also decreases the production of biphosphate-containing phospholipids, which are essential for dendritic cell maturation. The crystalline polymorphs have been characterized by X-ray diffraction and microscopy. Impurities can be detected using ultraviolet spectroscopy, infrared spectroscopy, or nuclear magnetic resonance spectroscopy.
Formula:C34H37FN2O5Purity:Min. 95%Color and Shape:PowderMolecular weight:572.67 g/molRef: 3D-IA18021
Discontinued product4-(Benzyloxy)butanoic acid
CAS:Formula:C11H14O3Purity:95%Color and Shape:LiquidMolecular weight:194.23Ref: 10-F210237
Discontinued product

